An analysis of the PURE study shows some gains but “little to no improvement in most places over time,” says Philip Joseph.
Regardless of country-level income classification, medications for the secondary prevention of CVD remains underutilized and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback